

AUTHOR CORRECTION

Author Correction to: Adjuvant Trastuzumab Therapy for Early HER2-Positive Breast Cancer in Iran: A Cost-Effectiveness and Scenario Analysis for an Optimal Treatment Strategy

Amir Ansaripour¹  · Carin A. Uyl-de Groot¹ · W. Ken Redekop¹

Published online: 23 February 2018
© Springer International Publishing AG, part of Springer Nature 2018

Author Correction to:
PharmacoEconomics (2018) 36(1):91–103
<https://doi.org/10.1007/s40273-017-0557-6>

In the print publication the data in Table 2, has been incorrectly published.

Page 95, Table 2, final row, second column: the mean Advanced treatment annual cost which

previously read
83,249

should read
8324

The original article can be found online at <https://doi.org/10.1007/s40273-017-0557-6>.

✉ Amir Ansaripour
ansaripour@bmg.eur.nl

¹ Institute for Medical Technology Assessment, Institute of Health Policy and Management, Erasmus University Rotterdam, PO Box 1738, 3000 DR Rotterdam, The Netherlands